Autres langues Innate Pharma

Actions

Temps réel Euronext Paris Autres places de cotation 13:49:03 10/06/2024			Varia. 5j.	Varia. 1 janv.
2,46 ^EUR	-2,96 %		-2,57 %	-6,11 %

04/06	Innate Pharma: résultats positifs pour le lacutamab	AO
04/06	Innate Pharma : données positives dans le mycosis fongoïde	CF

Innate Pharma : données positives dans le mycosis fongoïde	04/06
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides	04/06
Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides	04/06
Innate Pharma Announces Its Participation in Upcoming Investor Conferences	28/05
Innate Pharma : Feuille de présence (in French)	24/05
Innate Pharma : cinq abstracts sélectionnés pour l'ASCO	24/05
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting	24/05
Outcome of Innate Pharma’s 2024 Annual General Meeting	23/05
INNATE PHARMA SA - CLARIFICATION REGARDING SAR443579 DESIGNATION	22/05
Innate Pharma: Clarification Regarding SAR443579 Designation	21/05
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress	15/05
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results	14/05
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update	07/05
Innate Pharma : Notice of Convening 2024	06/05
Innate Pharma : Brochure AG	22/04
Innate Pharma : Report of the Executive Board at the Annual Shareholder's Meeting of May 2024	22/04
Innate Pharma : Table of Financial Resolutions 2024	22/04
Innate Pharma : Extraordinary and Ordinary General Meeting	17/04
INNATE PHARMA ANNOUNCES ADVANCEMENT OF SANOFI-DEVELOPED NK CELL ENGAGER SAR443579/IPH6101 PROGRESSING TO PHASE 2 FOR BLOOD CANCER PATIENTS	16/04
Sanofi : avancée d'un essai en hématologie	15/04

Aucun résultat pour cette recherche